Over the course of the projection period, it is anticipated that rising developments and product releases would fuel market expansion. For instance, scientists at IIT Bombay's Tata Institute for Technology and Design are currently attempting to create a locally produced CAR T-cell therapy that is inexpensive for cancer patients in India. A cutting-edge method of treating cancer that boosts the immune system is called immuno-oncology. The most well-known immune-oncology treatment, immune checkpoint inhibitors, has a remarkable overall success rate across a variety of cancers and has received numerous approvals. Even though immuno-oncology drugs are drastically altering the quality of life for people with cancer, managing toxicities and ensuring that healthcare systems are in place still present numerous obstacles. Moreover, a wide range of substances, including proteins, adjuvants, peptides, antibodies, bi-specific compounds, and cellular therapies, are included in the creation of immune-oncology medications.
According to Coherent Market Insights, The market for Immuno-oncology Medications in India is anticipated to reach US$ 265 Mn in 2021 and grow at a CAGR of 13.1% during the following five years (2021 -2028).
Major Players in the India Immune Oncology Drugs Industry:
1. Merck & Co., Inc.,
The business was founded in 1668, and Rahway, New Jersey serves as its corporate headquarters. Pharmaceuticals, vaccines, biologic therapies, and goods for animal health are all produced by Merck. The company announced in September 2022 that it will acquire the cattle management company Vence for an undisclosed sum and merge it with Merck Animal Health. Merck Animal Health acquired PrognostiX Poultry in February 2021.
2. Bristol-Myers Squibb
The firm was founded in 1887 and is located in New York, United States. The therapeutic areas in which Bristol Myers Squibb produces prescription drugs and biologics include cancer, HIV/AIDS, cardiovascular illness, insulin, hepatitis, rheumatoid arthritis, and mental conditions. BMS said in June 2022 that it would pay $4.1 billion in cash to purchase Turning Point Therapeutics Inc.
3. F. Hoffmann-La Roche AG.
The company was established in 1896 and is based in Basel, Switzerland. F. Hoffmann-La Roche AG offers in-vitro diagnostics, as well as cancer and transplant medications. Roche announced in March 2021 that it will pay $1.8 billion to purchase GenMark Diagnostics. The company announced in September 2021 that it will purchase the German biotech company TIB Molbiol in order to expand its molecular diagnostics business.
4. Mylan N.V.
The firm, founded in 1961, has its headquarters in Canonsburg, Pennsylvania, United States. The business manufactures active pharmaceutical ingredients, has a specialist division devoted to respiratory, allergy, and psychiatric therapies, and is a global generic and specialty medicines company. While the coronavirus 2019 (COVID-19) pandemic continues to evolve, Mylan stated in July 2020 that its Remdesivir would be commercially released in India under the brand name DESREMTM.
5. AstraZeneca plc
The organisation was founded in 1999 and the company's headquarter is located in Cambridge, United Kingdom. Its product line includes treatments for inflammatory, viral, neurological, respiratory, and heart disease. AstraZeneca declared its intention to buy CinCor Pharma for $1.8 billion in January 2023. The business declared in July 2022 that it will buy TeneoTwo for up to $1.3 billion, expanding its line of blood cancer medications.
6. Amgen Inc.,
The company was created in 1980 and has its headquarters in Thousand Oaks, California, United States. Amgen Inc. is a privately held biotechnology pharmaceutical firm that researches, develops, produces, and sells medications for severe illnesses. The business declared in March 2021 that it will pay $1.9 billion to buy Five Prime Therapeutics and its flagship drug, bemarituzumab. The business decided to buy ChemoCentryx for $3.7 billion in cash in August 2022.
7. Biocon Limited,
The company was founded in 1978 and has its headquarters in Bengaluru. The biosimilar assets of Viatris are purchased by Biocon Biologics in 2022 for $3.34 billion. An integrated biotechnology company, Biocon Ltd., has operations in the fields of biopharmaceuticals, enzymes, specialised research, and clinical research. Statins, immunosuppressants, and diabetes medications are among the company's pharmaceutical offerings.
Definition: The research and creation of cancer treatments that make use of the immune system of the body are known as immuno-oncology. A cutting-edge method of treating cancer is immuno-oncology, which boosts the immune system.
